Infinity's IPI-549 Gets Fast Track Tag For Urothelial Cancer
Zacks Investment Research | Mar 26, 2020 06:07AM ET
Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) were up 12% yesterday after the FDA granted a Fast Track designation to the combo of IPI-549 plus Bristol Myers’ (NYSE:BMY) Opdivo (nivolumab) for the treatment of advanced urothelial cancer, a type of bladder cancer.
However, the stock has plunged 48.2% in the past year compared with the industry’s decrease of 30.3%.
The fast track tag from the FDA is designed to provide certain benefits for new drugs/vaccines and expedite its review time for the same that treats serious or life-threatening conditions and demonstrates the potential to address the unmet medical needs.
Notably, during the fourth quarter of 2019, the company initiated MARIO-275, an ongoing, global, randomized, controlled phase II study in collaboration with Bristol-Myers Squibb, to evaluate IPI-549 in combination with the latter’s PD-1 immune checkpoint inhibitor Opdivo in platinum-refractory, I/O-naive patients with advanced urothelial cancer. Infinity is currently enrolling patients in the study. Completion of recruitment is expected in 2020 and data, by mid-2021.
We remind investors that Infinity is currently focused on developing its lead immuno-oncology candidate, IPI-549.
The company is evaluating IPI-549 as a monotherapy and in combination with Bristol-Myers’ Opdivo in a phase I/Ib study (MARIO-1) in about 200 patients afflicted with advanced solid tumors. The company completed enrolment in MARIO-1 during the fourth quarter. Additional findings from the study is expected later this year.
This apart, in September 2019, Infinity initiated a phase II MARIO-3 study in collaboration with Roche AG (OTC:RHHBY) evaluating IPI-549 in combination with Tecentriq and Abraxane (nab-paclitaxel) for the treatment of front-line triple negative breast cancer (TNBC). The above-mentioned study also includes a cohort evaluating IPI-549 in combination with Tecentriq and Avastin (bevacizumab) for front-line PDL1+ and PDL1- renal cell cancer (RCC) patients. Infinity plans to present the outcomes from the same later in 2020.
Meanwhile, Infinity in collaboration with Arcus Biosciences (NYSE:RCUS) is conducting an early-stage study to evaluate IPI-549 in combination with AB298, the latter's dual adenosine receptor antagonist, and Doxil, a chemotherapy, for treating patients with advanced TNBC.
Get The News You Want
If successfully developed in any of the studies and approved by the concerned regulatory agencies, IPI-549 will offer a huge boost to Infinity in the days ahead.
Zacks Rank
Infinity currently carries a Zacks Rank #3 (Hold). You can see .
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.5% per year.
These 7 were selected because of their superior potential for immediate breakout.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.